Bin Qian

Bin Qian has an extensive work experience in various companies and roles. Starting in 1999, they worked as a postdoctoral research fellow at the Medical College of Wisconsin until 2001. They then joined Chiron Corporation as a postdoctoral research fellow in 2002 before moving on to Bayhill Therapeutics in 2003, where they worked as a research scientist. At Bayhill Therapeutics, they conducted cell-based assays, characterized the activity of selected inhibitors, developed various assays, and supervised research associates. In 2009, they joined Geron as a research scientist until 2011 when they became the associate director of CT&BD at ReLIA Diagnostic Systems, Inc. They then worked as the assistant director of R&D at WondfoUSA from 2015 until 2016. In 2017, they became a tumor biologist at Varian Medical Systems until 2020. In 2021, they worked as a senior principal scientist at CellCarta and as a group leader at ET Healthcare. Currently, they are employed as a manager at Proxim Diagnostics since February 2023.

Bin Qian attended Nanjing University from 1988 to 1995 where they obtained an M.D degree from the School of Medicine.